Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)

BACKGROUND: In the FLAURA trial, superiority of osimertinib over the standard of care (SOC) was not demonstrated in Asian patients; SOC seemed favorable among Japanese patients (hazard ratio 1.39, 95% confidence interval 0.82–2.33). Three reasons are suggested: since rechallenge with epidermal growt...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Med Oncol
Autors principals: Morikawa, Kei, Tanaka, Hisashi, Itani, Hidetoshi, Takata, Saori, Watanabe, Satoshi, Kishi, Kazuma, Soejima, Kenzo, Kaira, Kyoichi, Kagamu, Hiroshi, Yoshimura, Kenichi, Matsutani, Noriyuki, Seki, Nobuhiko
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Advances in Treatment of Lung Cancer Patients with Targetable Mutations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7607717/
https://ncbi.nlm.nih.gov/pubmed/33193830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920967254
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars